{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:01:22Z","timestamp":1770274882879,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.pupt.2017.06.005","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T18:00:12Z","timestamp":1497981612000},"page":"147-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol"],"prefix":"10.1016","volume":"49","author":[{"given":"Rosario","family":"Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Sgura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Monopoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25 Suppl","key":"10.1016\/j.pupt.2017.06.005_bib1","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.pupt.2017.06.005_bib2","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.02.00068002","article-title":"Haemodynamic evaluation of pulmonary hypertension","volume":"20","author":"Chemla","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.06.005_bib3","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","year":"2009","journal-title":"Eur. Heart. J."},{"issue":"25 Suppl","key":"10.1016\/j.pupt.2017.06.005_bib4","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","author":"Gali\u00e8","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.pupt.2017.06.005_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.rmed.2009.11.015","article-title":"Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension","volume":"104","author":"Tonelli","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2017.06.005_bib6","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.06.005_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.108.794610","article-title":"Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study","volume":"119","author":"Skoro-Saier","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.06.005_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9149(85)90319-4","article-title":"Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension","volume":"55","author":"Rich","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.pupt.2017.06.005_bib9","doi-asserted-by":"crossref","first-page":"55A","DOI":"10.1016\/S0002-9149(99)80384-1","article-title":"Role of pharmacologic tests in the treatment of primary pulmonary hypertension","volume":"75","author":"Galie","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.pupt.2017.06.005_bib10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/01.CIR.84.3.1437","article-title":"Adenosine and selective reduction of pulmonary vascular resistance in primary pulmonary hypertension","volume":"84","author":"Reeves","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.06.005_bib11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1161\/01.CIR.84.3.1145","article-title":"Adenosine as a vasodilator in primary pulmonary hypertension","volume":"84","author":"Morgan","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.06.005_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0735-1097(93)90683-R","article-title":"Effects of adenosine in combination with calcium channel blockers in patient with primary pulmonary hypertension","volume":"21","author":"Inbar","year":"1993","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.pupt.2017.06.005_bib13","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1183\/09031936.96.09112401","article-title":"Medical management of primary pulmonary hypertension","volume":"9","author":"Kneussl","year":"1996","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.06.005_bib14","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1164\/ajrccm\/140.6.1623","article-title":"The acute administration of vasodilators in primary pulmonary hypertension. Experience from the national institutes of Health registry on primary pulmonary hypertension","volume":"140","author":"Weir","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"issue":"3 Suppl","key":"10.1016\/j.pupt.2017.06.005_bib15","doi-asserted-by":"crossref","first-page":"179S","DOI":"10.1378\/chest.93.3_Supplement.179S","article-title":"Comparison of acute hemodynamic responses to prostacyclin with standard vasodilators in patients with primary pulmonary hypertension","volume":"93","author":"Palevsky","year":"1988","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2017.06.005_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilatation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.06.005_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A\u00a0comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.pupt.2017.06.005_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pupt.2017.06.005_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.pupt.2017.06.005_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pupt.2017.06.005_bib21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.06.005_bib22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.pupt.2017.06.005_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","article-title":"Primary pulmonary hypertension","volume":"336","author":"Rubin","year":"1997","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.pupt.2017.06.005_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1476-5381.1983.tb10514.x","article-title":"The effect of adenyl compounds on the rat heart","volume":"79","author":"Burnstock","year":"1983","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pupt.2017.06.005_bib25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/01.RES.5.4.349","article-title":"Effects of adenine nucleotides on the contractility and membrane potentials of rat atrium","volume":"5","author":"Hollander","year":"1957","journal-title":"Circ. Res."},{"key":"10.1016\/j.pupt.2017.06.005_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0006-2952(73)90414-0","article-title":"The action of ATP in Guinea pig heart","volume":"22","author":"Hopkins","year":"1973","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.pupt.2017.06.005_bib27","first-page":"H734","article-title":"Isolated atrial myocytes: adenosine and acetylcholine increase potassium conductance","volume":"244","author":"Belardinelli","year":"1983","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.pupt.2017.06.005_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1113\/jphysiol.1988.sp017157","article-title":"ATP and other adenine compounds increase mechanical activity and inositol trisphosphate production in rat hearts","volume":"401","author":"Legssyer","year":"1988","journal-title":"J.\u00a0Physiol. (Lond)"},{"key":"10.1016\/j.pupt.2017.06.005_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0143-4160(88)90023-1","article-title":"Extracellular ATP has a potent effect to enhance cytosolic calcium and contractility in single ventricular myocytes","volume":"9","author":"Danziger","year":"1988","journal-title":"Cell. Calcium"},{"key":"10.1016\/j.pupt.2017.06.005_bib30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1254\/jjp.25.489","article-title":"Different inotropic responses to adenosine on the atrial and ventricular muscle of the dog heart","volume":"25","author":"Chiba","year":"1975","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.pupt.2017.06.005_bib31","first-page":"351A","article-title":"Micromolar extracellular ATP increases intracellular calcium concentration in isolated rat ventricular myocytes (abstract)","volume":"49","author":"Sharma","year":"1986","journal-title":"Biophys. J."},{"key":"10.1016\/j.pupt.2017.06.005_bib32","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.RES.67.4.1007","article-title":"The mechanism of positive inotropy induced by adenosine triphosphate in rat heart","volume":"67","author":"Scamps","year":"1990","journal-title":"Circ. Res."},{"key":"10.1016\/j.pupt.2017.06.005_bib33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/01.RES.68.2.482","article-title":"Effect of coronary hyperemia on Emax and oxygen consumption in blood-perfused rabbit hearts. Energetic consequences of Gregg's phenomenon","volume":"68","author":"Goto","year":"1991","journal-title":"Circ. Res."},{"key":"10.1016\/j.pupt.2017.06.005_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0033-0620(89)90015-7","article-title":"The cardiac effects of adenosine","volume":"32","author":"Belardinelli","year":"1989","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.pupt.2017.06.005_bib35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/01.CIR.85.3.893","article-title":"Protective effects of adenosine in myocardial ischemia","volume":"85","author":"Ely","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.06.005_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.CCM.0000105309.27519.27","article-title":"Adenosine infusion for the management of persistent pulmonary hypertension of the newborn","volume":"5","author":"Ng","year":"2004","journal-title":"Pediatr. Crit. Care. Med."},{"key":"10.1016\/j.pupt.2017.06.005_bib37","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0003-4975(96)00361-X","article-title":"Adenosine for refractory pulmonary hypertension","volume":"62","author":"Fullerton","year":"1996","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.pupt.2017.06.005_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","year":"2016","journal-title":"Eur. Heart. J."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917300135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917300135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T13:37:06Z","timestamp":1602337026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553917300135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":38,"alternative-id":["S1094553917300135"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2017.06.005","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2017.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}